Skip to main content

Table 3 Factors associated with tumor stage ≥ pT3 in entire cohort and each risk group

From: Performance characteristics of prostate-specific antigen density and biopsy core details to predict oncological outcome in patients with intermediate to high-risk prostate cancer underwent robot-assisted radical prostatectomy

  Entire cohort
  Univariate analyses   Multivariate analyses
  OR 95%CI p-value OR 95%CI p-value
PSAD >0.345 vs ≤0.345 ng/ml/cc 5.850 2.820–12.20 <0.001 4.370 2.000–9.540 <0.001
% positive cores >21.4 vs ≤21.4% 3.150 1.770–5.630 <0.001 2.100 1.110–3.990 0.028
% dominant side >37.5 vs ≤37.5% 2.210 1.250–3.910 0.006    
% cancer extent >55.6 vs ≤55.6% 2.600 1.450–4.650 0.001 1.960 1.030–3.720 0.041
NCCN risk high vs intermediate 2.440 1.380–4.320 0.002 1.910 1.020–3.580 0.042
  Intermediate-risk
  Univariate analyses   Multivariate analyses
  OR 95%CI p-value OR 95%CI p-value
PSAD >0.190 vs ≤0.190 ng/ml/cc 1.920 0.864–4.260 0.110    
% positive cores >21.4 vs ≤21.4% 3.260 1.450–7.320 0.004 3.260 1.450–7.320 0.004
% dominant side >36.4 vs ≤36.4% 2.400 1.070–5.380 0.033    
% cancer extent >57.1 vs ≤57.1% 2.180 0.970-4.900 0.059    
  High-risk
  Univariate analyses   Multivariate analyses
  OR 95%CI p-value OR 95%CI p-value
PSAD >0.345 vs ≤0.345 ng/ml/cc 4.730 1.680–13.30 0.003 4.510 1.580–12.90 0.004
% positive cores >35.0 vs ≤35.0% 3.140 1.180–8.390 0.023    
% dominant side >40.0 vs ≤40.0% 1.880 0.811–4.360 0.141    
% cancer extent >55.6 vs ≤55.6% 2.810 1.170–6.760 0.021    
  1. OR Odds ratio, 95%CI 95% confidence interval, % dominant side % positive cores from dominant side, % cancer extent maximum % of cancer extent in each positive core, Bold indicates statistically significant